5-amino-2-methyl-N-(2-methyl-1,3-thiazol-5-yl)benzamide | 942631-61-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-amino-2-methyl-N-(2-methyl-1,3-thiazol-5-yl)benzamide
• CAS: 942631-61-0
• 化学式: C₁₂H₁₃N₃OS
• 分子量: 247.321
• InChiKey: IJSDOXHJDLZBAV-UHFFFAOYSA-N

物化性质

• 沸点：
  377.9±37.0 °C(Predicted)
• 密度：
  1.330±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  96.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,5-二甲基苯甲酸 、 5-amino-2-methyl-N-(2-methyl-1,3-thiazol-5-yl)benzamide 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 5-[(3,5-dimethylbenzoyl)amino]-2-methyl-N-(2-methyl-1,3-thiazol-5-yl)benzamide
  参考文献：
  名称：

  Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer

  摘要：

  The bisamide class of kinase inhibitors was identified as being active against CSF-1R. The synthesis and SAR of pyridyl and thiazolyl bisamides is reported, along with the pharmacokinetic properties and in vivo activity of selected examples. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.07.093
• 作为产物：
  描述：

  tert-butyl (4-methyl-3-{[(2-methyl-1,3-thiazol-5-yl)amino]carbonyl}phenyl)carbamate 在 盐酸 、 甲醇 作用下， 生成 5-amino-2-methyl-N-(2-methyl-1,3-thiazol-5-yl)benzamide
  参考文献：
  名称：

  Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer

  摘要：

  The bisamide class of kinase inhibitors was identified as being active against CSF-1R. The synthesis and SAR of pyridyl and thiazolyl bisamides is reported, along with the pharmacokinetic properties and in vivo activity of selected examples. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.07.093

文献信息

• Chemical Compounds-149
  申请人：Aquila Brian

  公开号：US20080312206A1

  公开（公告）日：2008-12-18

  The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula which possess CSF 1R kinase inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

  本发明涉及一种化合物，或其药学上可接受的盐，其化学式如下，具有CSF 1R激酶抑制活性，因此在抗癌活性方面有用，并且在人或动物体的治疗方法中有用。本发明还涉及制造所述化合物的过程，含有它们的制药组合物以及它们在制造用于在温血动物（如人）中产生抗癌效果的药物中的使用。
• WO2007/71955
  申请人：——

  公开号：——

  公开（公告）日：——
• CHEMICAL COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1966174A1

  公开（公告）日：2008-09-10
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSES CHIMIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2007071955A1

  公开（公告）日：2007-06-28

  [EN] The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula which possess CSF 1R kinase inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
  [FR] L'invention concerne des composés chimiques, ou des sels de ceux-ci pharmaceutiquement acceptables de la formule (I), qui présentent une activité inhibitrice de CSF-1R kinase et qui sont par conséquent utiles de par leur activité anticancéreuse ainsi que dans des méthodes de traitement du corps humain ou animal. L'invention concerne également des procédés de fabrication de ces composés chimiques, des compositions pharmaceutiques les renfermant et leur utilisation dans la fabrication de médicaments à utiliser dans la production d'un effet anticancéreux chez un animal à sang chaud tel que l'humain.
• Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer
  作者：David A. Scott、Brian M. Aquila、Geraldine A. Bebernitz、Donald J. Cook、Les A. Dakin、Tracy L. Deegan、Maureen M. Hattersley、Stephanos Ioannidis、Paul D. Lyne、Charles A. Omer、Minwei Ye、XiaoLan Zheng

  DOI：10.1016/j.bmcl.2008.07.093

  日期：2008.9

  The bisamide class of kinase inhibitors was identified as being active against CSF-1R. The synthesis and SAR of pyridyl and thiazolyl bisamides is reported, along with the pharmacokinetic properties and in vivo activity of selected examples. (C) 2008 Elsevier Ltd. All rights reserved.